ads

Alzheimer’s Disease May Be Treated By Blocking Immune Response

Alzheimer’s Disease May Be Treated By Blocking Immune Response

Protein complex NLRP3 is the grave factor in Alzheimers disease’s development, the discovery was done by researchers from the German Center for Neurodegenerative Diseases (DZNE) and the University of Bonn.
Complex NLRP3 inflammasome was studied, which plays a very important part in the immune system. When the same is active, it mobilizes the immune cells and releases substances that cause inflammation.
Lot of study has been done over the last few years focusing on how the immune response of the body raises Alzheimer’s risk and also how certain genes are involved in this. Also another study has found how Alzheimer’s risk is linked to a genetic mutation in the TREM2 gene, which triggers immune system responses.
With Alzheimer’s disease once the sensor is active, it makes the nerve cell to die, which then result in loss of cognitive ability and brain function.
When the plaques starts forming in the brain Alzheimer’s disease occurs, NLRP3 inflammasome is activated by this plaque. The researchers studied the effect of this increase activity of inflammation that it has on the brain.
Prof. Michael Heneka and his team studied the brains on the patients that died of Alzheimer’s disease and mice that were having similar disorders which are related to Alzheimer’s disease. They found that in both the cases (human and mice) there was active NLRP3 inflammation.
Researchers believed that if by stopping the inflammatory reactions of the protein complex, damaging plaques will be reduced. So in the group of mice that had disorders linked with Alzheimer’s, researchers removed the genes that activate the NLRP3 inflammasome activity.
Once the gene was removed from the mice, they were not able to synthesize the protein complex. This in turn showed only a mild symptom of the disease.
This was an excellent news and the result could be that pharmaceuticals being able to target the protein complex and slow down the activity.
Prof. Heneka said:
“We have come across a critical factor in the development of Alzheimer’s. After these findings we have a very strong possibility now that we can block the activity of the inflammation. Currently tp act upon the course of the diseases various options are being tried. A new possibility has opened after the research. Yet, we are in the process of doing the basic research on it.”
The team is already searching the way to block inflammation. Prof. Heneka also said” The testing of that potential substance in the laboratory will be the next course of action and we hope to start it early next year”.